Latest Conference Articles

Joan Lunden Paints a Picture of Breast Cancer From the Patient's Perspective

Joan Lunden presented the keynote address at the Miami Breast Cancer Conference where she spoke powerfully and from the heart in a talk perfectly aligned with the meeting's focus on the patient perspective.

Heterogeneity Complicates Treatment Decisions in Breast Cancer

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

Hudis Highlights Interplay Between Inflammation, Obesity, and Breast Cancer

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

Dr. Sledge on Using Tumor Heterogeneity to Guide Treatment in Breast Cancer

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

Second-Line Ramucirumab Plus Docetaxel in Urothelial Cancer Improves Progression-Free Survival

Ramucirumab added to docetaxel significantly improved PFS compared with docetaxel monotherapy as second-line treatment in a phase II study of patients with metastatic transitional cell carcinoma.

Dr. Carey on Treating Triple-Negative Breast Cancer

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Pazopanib/Paclitaxel Combination Demonstrates Activity in Relapsed/Refractory Urothelial Cancer

In patients evaluable for treatment response, the ORR with the combination was 50%, with 11% having a CR.

Dr. Ryan on the Long Term Safety of Abiraterone Use

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

Early Intervention Essential for Proper Lymphedema Management

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

Driver Mutations Remain Prognostic But Not Predictive in Breast Cancer

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

Dr. Crawford Discusses Improving Risk Stratification in Prostate Cancer With the CCP Assay

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

Neoadjuvant Endocrine Therapy Appropriate in Select Patients

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate Cancer

Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

Abiraterone OS Benefit Prolonged After Crossover Adjustment in mCRPC

The beneficial effect of abiraterone acetate on overall survival in men with progressive metastatic CRPC in the COU-AA-302 study becomes even more pronounced after adjustment for crossover from placebo to active treatment.

Excitement Building for PARP Inhibitors in BRCA-Mutated Breast Cancer

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

No Survival Benefit From Adding Docetaxel to ADT in Hormone-Sensitive Prostate Cancer

Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed.

Immunointensification May Favorably Alter Survival in mCRPC

A phase I study conducted at the NIH, combining a fixed dose of PROSTVAC with escalating doses of the checkpoint inhibitor ipilimumab, produced encouraging survival results in mCRPC.

Dr. Tripathy on the Possibility of Curing Metastatic Breast Cancer

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.

Dr. Attai on What Physicians Can Learn from Social Media

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, explains how social media can help physicians.

Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

MBCC Embraces Revolution in Breast Cancer Care

The landscape of breast cancer care is shifting rapidly, but that doesn't worry the organizers of the 32nd Annual Miami Breast Cancer Conference.

Three Experts Examine the ER-Positive Treatment Landscape

With the evolution of treatment under way, OncLive interviewed three world-renowned experts in the field: Joanne L. Blum, MD, PhD, Adam M. Brufsky, MD, PhD, and Harold J. Burstein, MD, PhD.

Dr. McKay on Statin Use in Patients With mRCC

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

Dr. Sotomayor on Precision Medicine for the Prevention of Cancer

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses the future of personalized medicine in lymphoma.

Analysis Shows Increase in Higher-Risk Prostate Cancers

The proportion of men diagnosed with intermediate- or high-risk cancer, based on blood PSA level, increased by nearly 6% from 2011 to 2013.

Use With Caution: Active Surveillance in Patients With Intermediate-Risk Prostate Cancer

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients.

Sorafenib, Sunitinib Fail in Phase III Adjuvant RCC Trial

Neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with locally advanced renal cell carcinoma (RCC), according to results from the phase III ASSURE trial, which were presented at a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

Men with Testicular Cancer More Likely to Develop Prostate Cancer

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

AR-V7 Not Predictive of Chemo Outcomes in mCRPC, But May Still Have Prognostic Value

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.